Benign
paroxysmal positional vertigo after decompression sickness: a first case report and review of the literature.
Follow-up study of serum S100 protein concentrations demonstrated absence of normalization in the parameter in patients with psychomotor retardation and
paroxysmal syndrome, no normalization of MDA level found in examinees with EBD and psychomotor retardation.
Paroxysmal tonic upgaze of childhood and childhood absence epilepsy.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder, which is caused by a somatic mutation in the phosphatidylinositol glycan-complementation class A gene, with an estimated prevalence of 1-2 cases per million people in the United States (1-2).
The global
paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 5.8 billion by 2025 at an 11.2% CAGR during the forecast period, according to a new report by Grand View Research, Inc.
One-Year Efficacy of Ravulizumab (ALXN1210) in Adult Patients with
Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors, EHA Congress, June 13-16, 2019 Amsterdam, Netherlands, oral presentation, June 15, 2019, 12:00 p.m., abstract S863.
Classification, diagnostic criteria and management of benign
paroxysmal positional vertigo.
Diagnosis and management of benign
paroxysmal positional vertigo (BPPV).
A prespecified meta-analysis found high sensitivity and low specificity for
paroxysmal cough (sensitivity, 93.2%; specificity, 20.6%) and absence of fever (sensitivity, 81.8%; specificity, 18.8%).
United States Food and Drug Administration (USFDA) has approved Ultomiris (ravulizumab) injection intended for the treatment of adult patients with
paroxysmal nocturnal hemoglobinuria, it was reported yesterday.
To the Editor: Clinical symptom spectrum of
paroxysmal nocturnal hemoglobinuria (PNH) is consisted of chronic intravascular hemolysis, hemoglobinuria, relative bone marrow failure, and the rarity of thrombosis.[1] The neurological complications generated by PNH were almost exclusively a result of cerebral venous thrombosis.[1],[2],[3] However, moyamoya syndrome (MMS) secondary to PNH (PNH-MMS) is rarely described in the literature.[2],[3],[4],[5] We report herein a case of PNH-MMS to raise the awareness of this disease in PNH patients presenting with acute neurological deficits.